CD8A and neoplasm: When azacitidine and pembrolizumab were combined for chemotherapy-refractory metastatic colorectal patients, the levels of genomic DNA methylation and promoter region methylation were significantly downregulated, accompanied by up-regulation of immune-related genes and CD8+ tumor infiltrating lymphocyte density.90